Corrigendum: A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer.

B The survival numbers were incorrect. b A correction has been made to B I Results, Survival: i b B "PFS at 12, 18, and 24 months was 83.5% (95%CI: 77.6-89.7), 65.5 (95%CI: 57.6-74.4), and 53.1% (95%CI: 43.8-64.3), respectively. Keywords: chemoradiotherapy; immunotherapy; stage III; unresectable; NSCLC EN chemoradiotherapy immunotherapy stage III unresectable NSCLC 1 2 2 11/19/21 20211116 NES 211116 In the original article there was an error. Chemoradiotherapy, immunotherapy, unresectable, stage III, NSCLC. [Extracted from the article]